



Early Phase Development Solutions

Making every day of your journey count

With so many different regulatory requirements and scientific challenges in the early stages of drug development, it can be difficult to navigate a way forward, easily. Discover a clear path with Early Phase Development Solutions. It's a programmatic approach for meeting your drug development goals that teams you up with drug development leaders to prospectively plan and execute the required studies in an expedited way. By making every day of the journey count, Early Phase Development Solutions has helped hundreds of biotech firms reach their program goal up to 30 percent faster over the past three years.

Begin with the end in sight

Start off on the right track

Your vision for your molecule defines your entire program. From your development team and strategy to your contracts and financing, everything is customizable to your requirements.

Stay on course


Keep up to date on the details and progress of your program with regular status updates on your program timeline and proactive reports on potential risks to your candidate's development.

Achieve your program milestone

Reach your clinical goal faster with an approach that eliminates white space in your early drug development timeline and streamlines your transition from nonclinical to clinical development.

How far you go, is up to you

Whether you plan to complete an IND/CTA-enabling program or you need to gain the clinical insight that a first-in-human (FIH) or proof-of-concept (PoC) study can provide, you can enjoy the journey with a dedicated team and a singular, cohesive strategy.



Real-world benefits of a time-tested approach

Join more than 225 biotech ventures that have experienced the real-world benefits of a programmatic approach over the course of the past three years.

Partnership

A dedicated team that's with you for the entire journey

- Milestone Program Development
- Collaboration with Drug Development Leader and Project Manager
- Specialized expertise in nonclinical, clinical and regulatory
- Scientific and Risk Management

Continuity

A proactive strategy, from start to finish

- Multi-Study Operational Efficiency
- Interpretation and Connected Insights to Clinical Program Design
- Proactive Integration with Regulatory Strategy
- Next Step Recommendations

Added Value

An integrated and streamlined approach that adds value to your asset

- Estimated total program timeline and cost up front
- Flexible financial model
- Reach critical milestone dates on time

Learn more at drugdevelopment.labcorp.com/EPDS